Skip to main content
The Markets by Proactive
Go to Proactive Australia

Pharma & Biotech

e-Therapeutics: “significant room for upside”

After e-Therapeutics (LON:ETX) last week expanded on its investment plans in its final results for 2011, research boutique Edison Investment Research believes “significant room for upside remains” to the firm’s current enterprise value of £36 million.

e-Therapeutics has detailed plans for the £17 million it raised earlier this year, and has allocated up to £4 million for discovery and up to £10 million for clinical development. The firm is investing in the clinical development of its core research and development pipeline of four drugs as well as investing in building what Edison describes as a “broader in-house pipeline of new chemical entities” for possible future licensing to third parties.

Meanwhile, the firm is also strengthening its discovery capability by setting up a dedicated network pharmacology hub near Oxford, which should also help it secure strategic discovery collaborations with large and mid-tier pharmaceutical partners.

Edison said that core programmes (ETS2101 for cancer, ETX1153c for ‘C. difficile’ infections. ETS6103 for depression and ETX1153a for MRSA decolonisation” should start new clinical studies during 2012, with first data expected between the fourth quarter of 2012 and the second half of 2013. “Out-licensing deals with upfront payments, milestone and royalties should follow post-proof of concept,” added the research house.

Edison said that e-Therapeutics’ current enterprise value of £36 million (defined as market cap minus latest-reported cash) is supported by its three most-advanced core pipeline assets, valued at £43 million on a risk-adjusted net present valuation approach.

However, “significant room for upside remains” as the firm executes on its strategy, according to Edison, “crystallising further value from pipeline progress... and expansion as new candidates are generated by the discovery platform, and secures milestones and royalties from future collaboration/licensing deals”.

The research firm added that other sources of potential upside might come from developing current assets in additional indications, as well as clarity on development plans for clinical and earlier-stage assets undergoing commercial or intellectual property evaluation and e-Therapeutics’ collaboration with Kandewaal Laboratories in India.

For this year, Edison expects e-Therapeutics to make a loss of £3.9 million (2011: £2.7 milion).